# Neoadjuvant PD-1 Blockade in Patients with Stage IIB/C Melanoma

> **NCT03757689** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 63 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Pembrolizumab
- **PROCEDURE:** Wide Excision and Sentinel Lymph Node (SLN) Biopsy

## Key facts

- **NCT ID:** NCT03757689
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-05-06
- **Primary completion:** 2024-12-01
- **Final completion:** 2027-02
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2025-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03757689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03757689, "Neoadjuvant PD-1 Blockade in Patients with Stage IIB/C Melanoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03757689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*